MIRVASO (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) erythema of rosacea in adults 18 years of age or older.

Apply a pea-sized amount once daily to each of the five areas of the face: central forehead, chin, nose, each cheek. MIRVASO topical gel should be applied smoothly and evenly as a thin layer across the entire face avoiding the eyes and lips.

Wash hands after applying MIRVASO topical gel.

MIRVASO topical gel is for topical use only and not for oral, ophthalmic, or intravaginal use.

MIRVASO (brimonidine) topical gel, 0.33% is a white to light yellow opaque aqueous gel. Each gram of gel contains 5 mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base.

MIRVASO topical gel is contratindicated in patients who have experienced a hypersensitivity reaction to any component. Reactions have included angioedema, urticaria, and contact dermatitis [ see Warnings and Precautions (5.6)and Adverse Reactions (6.1, 6.2) ].

The following adverse drug reactions are discussed in greater detail in other sections of the label:

• Systemic Adverse Reactions of Alpha-2 Adrenergic Agonists [ see Warnings and Precautions ( 5.4) ]
• Local Vasomotor Adverse Reactions [ see Warnings and Precautions ( 5.5) ]
• Hypersensitivity [ see Warnings and Precautions ( 5.6) ]

No information is available on overdose in adults with MIRVASO topical gel.

Oral overdoses of other alpha-2 adrenergic agonists have been reported to cause symptoms such as hypotension, asthenia, vomiting, lethargy, sedation, bradycardia, arrhythmias, miosis, apnoea, hypotonia, hypothermia, respiratory depression, and seizure.

Treatment of an oral overdose includes supportive and symptomatic therapy; a patent airway should be maintained.

MIRVASO (brimonidine) topical gel, 0.33% contains brimonidine tartrate, an alpha adrenergic agonist.

The molecular formula of brimonidine tartrate is C 11H 10BrN 5• C 4H 6O 6. It has the following structural formula:

Chemically, brimonidine tartrate is 5-Bromo-6-(2-imidazolidinylideneamino) quinoxaline L-tartrate. Brimonidine tartrate has a molecular weight of 442.24 and appears as white to slightly yellowish powder.

Each gram of MIRVASO (brimonidine) topical gel, 0.33% contains 5 mg of the active ingredient brimonidine tartrate (equivalent to 3.3 mg of brimonidine free base), in a white to light yellow opaque gel composed of the inactive ingredients carbomer homopolymer type B, glycerin, methylparaben, phenoxyethanol, propylene glycol, purified water, sodium hydroxide, and titanium dioxide.

MIRVASO topical gel was evaluated for the treatment of moderate to severe, persistent (nontransient) facial erythema of rosacea in two randomized, double-blind, vehicle-controlled clinical trials, which were identical in design. The trials were conducted in 553 subjects aged 18 years and older who were treated once daily for 4 weeks with either MIRVASO topical gel or vehicle. Overall, 99% of subjects were Caucasian and 76% were female. Baseline disease severity was graded using a 5-point Clinical Erythema Assessment (CEA) scale and a 5-point Patient Self Assessment (PSA) scale, on which subjects scored either “moderate” or “severe” on both scales.

The primary efficacy endpoint in both pivotal trials was 2-grade Composite Success, defined as the proportion of subjects with a 2-grade improvement on both CEA and PSA measured at hours 3, 6, 9, and 12 on Day 29. Table 2 presents the efficacy results. In addition to Day 29, efficacy was evaluated on Day 15 and Day 1, and the results are presented in Figures 1 and 2 for Studies 1 and 2, respectively.

2-grade Composite Success: 2-grade improvement on CEA and 2-grade improvement on PSA.         

MIRVASO (brimonidine) topical gel, 0.33% is a white to light yellow opaque gel, supplied in a laminated tube or pump with a child resistant cap in the following sizes:

30 gram tube NDC0299-5980-30

30 gram pump NDC0299-5980-35

45 gram tube NDC0299-5980-45

Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F) [See USP Controlled Room Temperature].

See FDA-approved patient labeling (Patient Information and Instructions for Use)

Patients using MIRVASO topical gel should receive the following information and instructions:

• This medication is to be used as directed by the physician.
• It is for external use only.
• MIRVASO topical gel should not be applied to irritated skin or open wounds.
• Avoid contact with the eyes and lips.
• Patients should wash their hands immediately after applying the medication.
• Some patients using MIRVASO topical gel may experience erythema, flushing or excessive whitening.
• Patients should report any adverse reactions to their physician.
• Keep out of reach of children.

Marketed by:

GALDERMA LABORATORIES, L.P., Fort Worth, Texas 76177 USA

Made in Canada.

All trademarks are the property of their respective owners.

P52849-2 or P51217-3

MIRVASO (Mer-VAY-soe)
(brimonidine)
topical gel

Important information:MIRVASO ®topical gel is for use on the face only. Do not use MIRVASO topical gel in your eyes, mouth, or vagina.
Keep MIRVASO topical gel out of the reach of children.
If anyone, especially a child, accidentally swallows MIRVASO topical gel, they may have serious side effects and need to be treated in a hospital. Get medical help right away if you, a child, or anyone else swallows MIRVASO topical gel and has any of these symptoms:
• lack of energy, trouble breathing or stops breathing, a slow heart beat, confusion, sweating, restlessness, muscle spasms, or twitching.

What is MIRVASO topical gel?
MIRVASO topical gel is a prescription medicine that is used on your skin (topical) to treat facial redness due to rosacea that does not go away (persistent) in adults who are 18 years of age or older.

It is not known if MIRVASO topical gel is safe and effective in children.

Who should not use MIRVASO topical gel?

Do not use MIRVASO topical gel if youhave had a serious allergic reaction to any of the ingredients in MIRVASO topical gel. See the end of this Patient Information leaflet for a list of ingredients in MIRVASO topical gel. See “What are the possible side effects of MIRVASO topical gel?”

What should I tell my doctor before using MIRVASO topical gel?
Before using MIRVASO topical gel, tell your doctor about all of your medical conditions including if you:

• have depression
• have heart or blood vessel problems
• have dizziness or blood pressure problems
• have problems with blood circulation or have had a stroke
• have dry mouth or Sjögren’s Syndrome
• have skin tightening or scleroderma
• have Raynaud’s phenomenon
• have irritated skin or open sores
• plan to have any laser procedures
• are pregnant or plan to become pregnant. It is not known if MIRVASO topical gel will harm your unborn baby.
• are breastfeeding. It is not known if MIRVASO topical gel passes into your breast milk. You and your doctor should decide if you will use MIRVASO topical gel or breastfeed. You should not do both.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, skin products, vitamins, and herbal supplements. Using MIRVASO topical gel with certain other medicines may affect each other and can cause serious side effects.

How should I use MIRVASO topical gel?

See the detailed Instructions for Use that comes with your MIRVASO topical gel tube or pump for information about how to apply MIRVASO topical gel correctly.

• Use MIRVASO topical gel exactly as your doctor tells you.Do not use more MIRVASO topical gel than prescribed. Call your doctor if you are not sure.
• You should not apply MIRVASO topical gel to irritated skin or open wounds.
• MIRVASO topical gel is for use on your skin only. Do not use MIRVASO topical gel in your eyes, mouth, or vagina. Avoid contact with your lips and eyes.

What are the possible side effects of MIRVASO topical gel?

MIRVASO topical gel may cause serious side effects, including:

• See “Important information” at the beginning of this Patient Information leaflet.

• Problems with blood circulation.People who use MIRVASO topical gel can have problems with blood circulation, including a slow heart rate, low blood pressure, and dizziness. These problems may sometimes be serious and lead to hospitalization. See “What should I tell my doctor before using MIRVASO topical gel?”

• Serious allergic (hypersensitivity) reactionshave happened in people who use MIRVASO topical gel. Stop using MIRVASO topical gel and go to the nearest hospital emergency room right away if you have any of the following signs and symptoms of a serious allergic reaction including:

o swelling of your face, lips, tongue, or throat
o hives
o trouble breathing

The most common side effects of MIRVASO topical gel include:

• redness • flushing • burning sensation of the skin • skin reactions (contact dermatitis).

Skin redness is common after applying MIRVASO topical gel, and may be worse than before you applied it. You may also develop redness on areas of your face that were not affected by rosacea, as well as on your neck and chest.

Skin flushing is common and may happen off and on after applying MIRVASO topical gel. In some cases, the flushing may be new, may happen more often, or you may have increased redness with flushing.

Pale colored skin or very white skin (excessive whitening) can happen at or outside the treated area.

Tell your doctor if you get skin redness, flushing, and pale colored skin that is uncomfortable for you.

These are not all the possible side effects of MIRVASO topical gel.

Call your doctor for medical advice about side effects.  You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of MIRVASO topical gel
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or doctor for information about MIRVASO topical gel that is written for health professionals. Do not use MIRVASO topical gel for a condition for which it was not prescribed. Do not give MIRVASO topical gel to other people, even if they have the same symptoms that you have. It may harm them.

What are the ingredients in MIRVASO topical gel?

Active ingredient: brimonidine
Inactive ingredients: carbomer homopolymer type B, glycerin, methylparaben, phenoxyethanol, propylene glycol, purified water, sodium hydroxide, titanium dioxide.

Marketed by: GALDERMA LABORATORIES, L.P., Fort Worth, TX 76177 USA

Made in Canada.

This Patient Information has been approved by the U.S. Food and Drug Administration.
Revised: Nov 2017

Instructions for Use
MIRVASO (Mer-VAY-soe)
(brimonidine)topical geltube

Important:MIRVASO ®topical gel is for use on the face only. Do not use MIRVASO topical gel in your eyes, mouth, or vagina.

Keep MIRVASO topical gel out of the reach of children.
If anyone, especially a child, accidentally swallows MIRVASO topical gel, they may have serious side effects and need to be treated in a hospital. Get medical help right away if you, a child, or anyone else swallows MIRVASO topical gel and has any of these symptoms:
• lack of energy, trouble breathing or stops breathing, a slow heart beat, confusion, sweating, restlessness, muscle spasms, or twitching.

Read and follow the steps below so that you use your tube of MIRVASO topical gel correctly:
1. Open the tube of MIRVASO topical gel by gently pressing down on the child resistant cap and twist in the direction of the arrow as shown below (counterclockwise). See Figures A and B. To avoid spilling, do not squeeze the tube while opening or closing.

Figure A

Figure B

2. To apply MIRVASO topical gel to your face, squeeze a pea-sized amount of MIRVASO topical gel from the tube onto your fingertip. See Figure C.

Figure C

3. Apply a pea-sized amount of MIRVASO topical gel onto each of the five areas of your face (forehead, chin,
    nose, each cheek) 1 time each day. You will use a total of 5 pea-sized amounts of MIRVASO
    topical gel. Spread the gel smoothly and evenly in a thin layer over your face.
    Avoid contact with your eyes and lips. Do not apply MIRVASO topical gel to irritated skin or open wounds.

4. To close your MIRVASO topical gel tube, place the cap back on the tube. Gently press down on the child resistant cap and twist to the right (clockwise). See Figure D.

Figure D

5. Wash your hands right away after applying MIRVASO topical gel.

How should I store MIRVASO topical gel?

• Store MIRVASO topical gel at room temperature between 68°F to 77°F (20°C to 25°C).

Keep MIRVASO topical gel and all medicines out of the reach of children.

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

Marketed by: GALDERMA LABORATORIES, L.P.
Fort Worth, TX 76177 USA
Made in Canada.
Revised: October 2015

Instructions for Use
MIRVASO (Mer-VAY-soe)
(brimonidine)topical gelPump

Important:MIRVASO ®topical gel is for use on the face only. Do not use MIRVASO topical gel in your eyes, mouth, or vagina.

Keep MIRVASO topical gel out of the reach of children.

If anyone, especially a child, accidentally swallows MIRVASO topical gel, they may have serious side effects and need to be treated in a hospital. Get medical help right away if you, a child, or anyone else swallows MIRVASO topical gel and has any of these symptoms:

• lack of energy, trouble breathing or stops breathing, a slow heart beat, confusion, sweating, restlessness, muscle spasms, or twitching.

Read and follow the steps below so that you use your MIRVASO topical gel correctly:

1. Push the cap down and turn it counter-clockwise until the cap can be removed. See Figures A and B. The clear sticker will break when opening for the first time.
Note:when the cap is removed, the pump is not child-resistant.

Figure A

Figure B

Figure C

Before the first use, prime the pump by pressing down several times until the medicine is dispensed onto your fingertip.

2. To apply MIRVASO topical gel to your face, dispense a pea-sized amount of MIRVASO topical gel from the pump onto your fingertip. See Figure C.

3. Apply a pea-sized amount of MIRVASO topical gel onto each of the five areas of your face (forehead, chin, nose, each cheek) 1 time each day. You will use a total of 5 pea-sized amounts of MIRVASO topical gel. Spread the gel smoothly and evenly in a thin layer over your face. Avoid contact with your eyes and lips. Do not apply MIRVASO topical gel to irritated skin or open wounds.

4. To close your MIRVASO topical gel pump, place the cap back on the pump. Push down and turn the cap to the right (clockwise) until it stops. This pump is child-resistant again. See Figure D.

Figure D

5. Wash your hands right away after applying MIRVASO topical gel.

How should I store MIRVASO topical gel?

• Store MIRVASO topical gel at room temperature between 68°F to 77°F (20°C to 25°C).

Keep MIRVASO topical gel and all medicines out of the reach of children.

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

Marketed by: GALDERMA LABORATORIES, L.P., Fort Worth, TX 76177 USA,
Made in Canada
Issued: November 2017 

Rx Only
NDC 0299-5980-35

Mirvaso ®
(brimonidine) topical gel, 0.33%*
PUMP

*Each gram of Mirvaso topical gel contains 5 mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base

For Topical Use Only
Keep Out of Reach of Children

GALDERMA
NET WT. 30 g

Not for oral, ophthalmic or intravaginal use.

To Open Pump:Push the cap down while turning it counter-clockwise to remove the cap.

Usual Dosage:Apply a pea-size amount once daily to each of the five areas of the face (forehead, chin, nose, and each cheek) avoiding the eyes and lips. See package insert for complete prescribing information.

Each gramcontains the activeingredient brimonidine tartrate 5mg with the inactiveingredients carbomer homopolymer type B, glycerin, methylparaben, phenoxyethanol, propylene glycol, purified water, sodium hydroxide, and titanium dioxide.

Storage:Store at 20° to 25°C (68° to 77°F), excursions permitted between 15° and 30°C (59° and 86°F). [See USP Controlled Room Temperature].

See bottom of carton for lot number and expiration date.

All trademarks are the property of their respective owners.

Marketed by:
GALDERMA LABORATORIES, L.P.
Dallas, TX 75201 USA
Made in Canada
P52848-3